Emmanuelle Salort‐Campana

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies

Yves Allenbach, Laurent Drouot, Aude Rigolet et al. · Medicine · 2014 · 267 citations · Full text

Immunohematology, Immunodeficiencies, Immunology +21

High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody

Yves Allenbach, Jérémy Keraen, Anne‐Marie Bouvier et al. · Brain · 2016 · 263 citations · Full text

Immunology, Pathology, Immunotherapy +17

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 169 citations · Full text

Late-onset Pompe Disease, Autoimmune Disease, Clinical Infectious Disease +3

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 154 citations · Full text

Alzheimer's Disease, Open-label Extension Study, Medicine +5